XTRA:CURK

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

curasan AG develops, produces, and markets biomaterials and medical devices for bone and tissue regeneration worldwide. More Details


Snowflake Analysis

Mediocre balance sheet and overvalued.

Share Price & News

How has curasan's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CURK's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

CURK

-7.6%

DE Biotechs

-1.9%

DE Market


1 Year Return

-87.5%

CURK

-5.4%

DE Biotechs

0.2%

DE Market

Return vs Industry: CURK underperformed the German Biotechs industry which returned -5.4% over the past year.

Return vs Market: CURK underperformed the German Market which returned 0.1% over the past year.


Shareholder returns

CURKIndustryMarket
7 Day0%-7.6%-1.9%
30 Day-6.5%-11.3%0.8%
90 Day61.5%-12.2%-0.5%
1 Year-87.5%-87.5%-5.3%-5.4%3.4%0.2%
3 Year-96.3%-96.3%-0.2%-1.1%-0.2%-9.0%
5 Year-96.0%-96.4%39.7%37.5%21.4%4.0%

Price Volatility Vs. Market

How volatile is curasan's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is curasan undervalued compared to its fair value and its price relative to the market?

0.19x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CURK's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CURK's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CURK is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.

PE vs Market: CURK is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CURK's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CURK is good value based on its PB Ratio (0.2x) compared to the DE Biotechs industry average (3.9x).


Next Steps

Future Growth

How is curasan forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

39.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as curasan has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has curasan performed over the past 5 years?

-39.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CURK is currently unprofitable.

Growing Profit Margin: CURK is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CURK is unprofitable, and losses have increased over the past 5 years at a rate of 39.4% per year.

Accelerating Growth: Unable to compare CURK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CURK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (15.2%).


Return on Equity

High ROE: CURK has a negative Return on Equity (-75.33%), as it is currently unprofitable.


Next Steps

Financial Health

How is curasan's financial position?


Financial Position Analysis

Short Term Liabilities: CURK's short term assets (€5.1M) exceed its short term liabilities (€2.4M).

Long Term Liabilities: CURK's short term assets (€5.1M) exceed its long term liabilities (€2.0M).


Debt to Equity History and Analysis

Debt Level: CURK's debt to equity ratio (30.1%) is considered satisfactory.

Reducing Debt: CURK's debt to equity ratio has increased from 0.7% to 30.1% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if CURK has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if CURK has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is curasan current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CURK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CURK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CURK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CURK's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: CURK is not paying a notable dividend for the German market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CURK's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.4yrs

Average management tenure


CEO

Alexander Baratta

0.58

Tenure

Dr. Alexander Baratta serves as Chief Executive Officer at curasan AG since March 16, 2020 and serves as its Chairman of Management Board since March 16, 2020.


Leadership Team

NamePositionTenureCompensationOwnership
Alexander Baratta
Chairman of Management Board & CEO0.58yrno datano data
Fabian Peters
Technical Directorno datano datano data
Andrea Weidner
Head of Corporate Communications & Investor Relationsno datano datano data
Gregor Siebert
Head of Marketing & Sales5.5yrsno datano data
Shane Ray
President of USA4.42yrsno datano data

4.4yrs

Average Tenure

Experienced Management: CURK's management team is considered experienced (4.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

curasan AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: curasan AG
  • Ticker: CURK
  • Exchange: XTRA
  • Founded: 1988
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €1.179m
  • Shares outstanding: 9.07m
  • Website: https://www.curasan.de

Number of Employees


Location

  • curasan AG
  • Lindigstrasse 4
  • Kleinostheim
  • Bavaria
  • 63801
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CURKDB (Deutsche Boerse AG)YesBearer SharesDEEURJul 2000
CURKXTRA (XETRA Trading Platform)YesBearer SharesDEEURJul 2000

Biography

curasan AG develops, produces, and markets biomaterials and medical devices for bone and tissue regeneration worldwide. The company specializes in offering biomimetic bone regeneration materials, which are ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/24 20:44
End of Day Share Price2020/09/29 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.